Stocks
Novo's series of unfortunate events
Eli wins this round, while Novo continues to flounder.
Eli wins this round, while Novo continues to flounder.
Shares sank on the news.
The end of the government shutdown is the beginning of problems for healthcare stocks.
The two pharma companies are duking it out for the future of weight-loss drugs.
President Trump's unplanned remarks took a toll on Novo Nordisk and Eli Lilly.
Both pharma giants are working to create new obesity pills.
Martin Shkreli is shorting a pharmaceutical company, and people are listening to him for some reason.
Stay up to date on the latest market news with daily analysis of the investing landscape, served up Brew-style.
By subscribing, you accept our Terms & Privacy Policy.